Clinical Trial

Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

Name: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma — clinical trial record (NCT06961617)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.

Trial Details

NCT Number	NCT06961617
Lead Sponsor	Lion TCR Pte. Ltd. Collaborators: Beijing GoBroad Hospital
Conditions	Hepatocellular Carcinoma
Enrollment	10 participants
Start Date	2024-06-01
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-08